What are the adverse effects of N‑acetylcysteine (NAC) when given orally and intravenously?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 15, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Adverse Effects of N-Acetylcysteine (NAC)

NAC is generally well-tolerated with manageable adverse effects, but clinicians must be vigilant for hypersensitivity reactions, particularly with intravenous administration, which occur in approximately 17% of patients and most commonly manifest during the initial loading dose.

Route-Specific Adverse Effects

Oral NAC

When administered orally, NAC has relatively few side effects 1:

  • Gastrointestinal symptoms: Nausea, vomiting, and diarrhea are the most common complaints
  • Rare reactions: Urticaria or bronchospasm occur infrequently
  • These effects are generally mild and self-limiting

The oral route is often preferred when feasible, though it may be precluded in acute liver failure patients with active gastrointestinal bleeding or worsening mental status 1.

Intravenous NAC

Intravenous administration carries a higher risk of acute hypersensitivity reactions, occurring in 17% of patients overall, with most reactions developing within the first 2 hours of infusion 2.

Common Hypersensitivity Reactions (occur in 0.2-21% of patients):

  • Dermatologic: Rash, urticaria, pruritus, acute flushing and erythema (most frequent) 3, 2
  • Respiratory: Bronchospasm, wheezing, shortness of breath 2
  • Cardiovascular: Hypotension, tachycardia 2
  • Other: Angioedema 2

These reactions typically occur 30-60 minutes after initiating the infusion and often resolve spontaneously despite continued infusion 2. The reactions are anaphylactoid (non-immunological) rather than true anaphylaxis, with histamine appearing to be an important mediator 4.

High-Risk Patient Groups:

  • Females are at increased risk 4
  • Patients with asthma or atopy are particularly susceptible 2, 4
  • Lower serum acetaminophen concentrations paradoxically increase risk—higher acetaminophen levels appear protective against anaphylactoid effects 4

Serious Adverse Events:

  • Fatal bronchospasm: One documented death occurred in a patient with asthma who received intravenous NAC 2
  • Fluid overload: Can result in hyponatremia, seizure, and death if volume is not adjusted appropriately, particularly in patients <40 kg or those requiring fluid restriction 2
  • Cerebral edema and brain death: Rare case reports describe devastating outcomes with large inadvertent NAC overdoses (6-fold dosing errors), including seizures, cerebral edema, brain herniation, and brain death 5

Management of Adverse Reactions

For Mild Reactions (flushing, erythema alone):

  • Continue infusion with close monitoring
  • These often resolve spontaneously 2

For Moderate Hypersensitivity Reactions:

  • Temporarily interrupt the infusion
  • Administer antihistamines
  • May carefully restart infusion after symptoms are controlled 1, 2

For Severe Hypersensitivity Reactions:

  • Immediately stop the NAC infusion
  • Administer antihistamines
  • Use epinephrine for bronchospasm 1
  • If reaction returns upon re-initiation or increases in severity, discontinue NAC and consider alternative management 2

Critical Safety Considerations

Patients with asthma require particularly close monitoring during NAC initiation and throughout therapy 2. Despite the risk of adverse effects, these should not preclude patients from receiving maximal hepatic protection, especially with significant acetaminophen ingestion 4.

The complex dosing schedule of intravenous NAC creates a high incidence of medication errors 5. Institutions should review their NAC ordering, dosing, and mixing protocols to prevent potentially fatal dosing errors 5.

The skin rash incidence is <5% and transient bronchospasm occurs in 1-2% of patients 3. Gastrointestinal effects (nausea, vomiting, diarrhea, constipation) are common with both routes but are generally manageable 3.

References

4
Research

Adverse reactions associated with acetylcysteine.

Clinical toxicology (Philadelphia, Pa.), 2009

Related Questions

What is the appropriate oral dosing regimen of N‑acetylcysteine (NAC) 600 mg sachets for a 16‑year‑old female weighing approximately 60 kg?
After giving intravenous N‑acetylcysteine to a female patient who suddenly feels relief of chest congestion, should I continue the infusion and what monitoring is required?
What are the contraindications for N‑acetylcysteine (NAC)?
What is the appropriate dose of N‑acetylcysteine (NAC) for a child weighing 29 kg?
What are the recommended dosing, contraindications, and monitoring considerations for N‑acetylcysteine (NAC) in elderly patients?
In a 60‑kg breastfeeding woman with an HbA1c of 10.2% and no known renal impairment, can metformin be started at 500 mg twice daily?
In an obese patient with leg swelling, tenderness, and pain on walking, a normal echocardiogram, and no deep vein thrombosis, what additional diagnostic steps should be performed?
In a 60‑kg breastfeeding woman with HbA1c 10.2% and normal renal function, can gliclazide be added to insulin therapy safely regarding hypoglycemia?
Should patients be instructed to rinse their mouth after using Airsupra (fluticasone propionate)?
In a 60‑kg non‑postpartum woman with HbA1c 10.2% and normal renal function who is on insulin, how should gliclazide be started and the insulin dose be adjusted?
Which laboratory tests should be obtained to evaluate the gallbladder in a patient who has already had a CT scan?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.